Welcome
Support Centre
21 March 2013 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
SentiMAG multicentre trial
ISRCTN ISRCTN35827879
DOI 10.1186/ISRCTN35827879
ClinicalTrials.gov identifier
EudraCT number
Public title SentiMAG multicentre trial
Scientific title Sentinel node biopsy using MAGnetic nanoparticles: A prospective multicentre phase II non-randomised clinical trial to compare sentinel node biopsy using magnetic nanoparticles vs. standard technique
Acronym SentiMAG
Serial number at source 11/LO/1972
Study hypothesis The standard Sentinel Lymph Node Biopsy (SLNB) technique (patent blue dye and radioisotope; or radioisotope alone) used in breast cancer patients has several drawbacks. The use of radioisotope exposes patients and healthcare workers to radiation, is heavily controlled by legislation (both on the specific training for operators and subsequent disposal of surgical waste), and provides poor pre-operative imaging.

The SentiMAG multicentre trial evaluates a new technique for SLNB against the standard technique. This new technique uses two devices: a subcutaneous injection of a magnetic tracer (Sienna+) into the breast and the use of a hand-held device (a magnetometer, SentiMag) to detect the sentinel node(s) intraoperatively.
Lay summary http://www.cancerresearchuk.org/cancer-help/trials/a-study-looking-new-way-find-sentinel-lymph-nodes-breast-cancer-sentimag
Ethics approval NRES Committee London - London Bridge ,06th February 2012, ref: 11/LO/1972
Study design Prospective multicentre phase II non-randomised clinical trial
Countries of recruitment Netherlands, United Kingdom
Disease/condition/study domain Breast Cancer
Participants - inclusion criteria 1. Patients with breast cancer scheduled for SLNB and who are clinically and radiologically (pre-operative ultrasound normal or indeterminate/abnormal and benign FNA or core biopsy) node negative
2. Patients available for follow-up for at least 12 months
Participants - exclusion criteria 1. Intolerance / hypersensitivity to iron or dextran compounds or Sienna +
2. Patients who cannot / do not receive radioisotope for SLNB
3. Patients with an iron overload disease
4. Patients with pacemakers or other implantable devices in the chest-wall
5. Intolerance / hypersensitivity to patent blue dye in centres where this is used routinely
Anticipated start date 01/02/2012
Anticipated end date 01/02/2017
Status of trial Ongoing
Patient information material Not available in web format, please use the contact details to request a patient information sheet
Target number of participants 160
Interventions SLNB with the standard (patent blue dye and radioisotope; or radioisotope alone) or the new technique (magnetic tracer and hand-held magnetometer). Interventions are the injection of the radioisotope, blue dye and magnetic tracer. Furthermore the detection and localization of the sentinel lymph node with gammaprobe and the hand-held magnetometer.

Pre- and post contrast MRI scan of the axilla.

Details of secondary sponsor:
Guy's and St. Thomas' NHS Foundation Trust
Westminster Bridge Rd
London Borough of Lambeth
London SE1 7EH
UK
Primary outcome measure(s) SLNB technique: The proportion of sentinel nodes detected (detection rate) with either the standard (patent blue dye and radioisotope; or radioisotope alone) or the new technique (magnetic tracer and hand-held magnetometer).

MRI sub protocol: Accuracy of MRI for the localisation of SLNs.
Secondary outcome measure(s) Morbidity from SLNB including lymphoedema, numbness, seroma, cutaneous staining, shoulder stiffness, chronic pain and locoregional recurrence.
Sources of funding King's College London (UK)
Trial website
Publications
Contact name Mr  Michael  Douek
  Address King's College London
Dept of Research Oncology
3rd Floor Bermondsey Wing
Guy's Hospital
Great Maze Pond
  City/town London
  Zip/Postcode SE1 9RT
  Country United Kingdom
  Email janet.mac_sweeney@kcl.ac.uk
Sponsor King's College London (UK)
  Address Room 1.8 Hodgkin Building
Guy's Campus
  City/town London
  Zip/Postcode SE1 1UL
  Country United Kingdom
  Sponsor website: http://www.kcl.ac.uk
Date applied 29/11/2012
Last edited 08/03/2013
Date ISRCTN assigned 19/02/2013
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2013 ISRCTN unless otherwise stated.